$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2020 Form 10-K Financial Statement

#000162828020010734 Filed on July 28, 2020

Income Statement

Concept	2020	2019 Q2	2019
Revenue	$32.12M	$7.720M	$2.900M
YoY Change	1007.69%	56.91%	-85.67%
Cost Of Revenue	$17.00M	$4.300M	$14.27M
YoY Change	19.13%	52.48%	35.26%
Gross Profit	$15.12M	$3.420M	$12.80M
YoY Change	18.15%	62.09%	32.09%
Gross Profit Margin	47.08%	44.3%	441.38%
Selling, General & Admin	$10.86M	$2.290M	$7.734M
YoY Change	40.37%	42.24%	16.46%
% of Gross Profit	71.78%	66.96%	60.42%
Research & Development	$5.853M	$1.250M	$4.798M
YoY Change	21.99%	14.68%	9.02%
% of Gross Profit	38.7%	36.55%	37.48%
Depreciation & Amortization	$825.0K	$180.0K	$606.0K
YoY Change	36.14%	63.64%	68.33%
% of Gross Profit	5.46%	5.26%	4.73%
Operating Expenses	$33.93M	$3.540M	$26.80M
YoY Change	26.6%	31.11%	24.09%
Operating Profit	-$1.921M	-$120.0K	$270.0K
YoY Change	-811.48%	-79.66%	-119.94%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$42.00K	-$30.00K	-$39.00K
YoY Change	7.69%	50.0%	-56.18%
Pretax Income	-$1.963M	-$150.0K	$231.0K
YoY Change	-949.78%	-75.81%	-116.01%
Income Tax	$130.0K	$100.0K	$103.0K
% Of Pretax Income			44.59%
Net Earnings	-$2.093M	-$250.0K	$128.0K
YoY Change	-1735.16%	-60.32%	-108.67%
Net Earnings / Revenue	-6.52%	-3.24%	4.41%
Basic Earnings Per Share	-$0.18		$0.01
Diluted Earnings Per Share	-$0.18	-$21.57K	$0.01
COMMON SHARES
Basic Shares Outstanding	11.84M shares		11.34M shares
Diluted Shares Outstanding	11.84M shares		14.10M shares

Balance Sheet

Concept	2020	2019 Q2	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.340M	$3.240M	$3.240M
YoY Change	157.41%	276.74%	276.74%
Cash & Equivalents	$8.340M	$3.237M	$3.240M
Short-Term Investments
Other Short-Term Assets	$390.0K	$310.0K	$310.0K
YoY Change	25.81%	6.9%	6.9%
Inventory
Prepaid Expenses
Receivables	$4.770M	$4.377M	$4.380M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$13.50M	$7.922M	$7.920M
YoY Change	70.45%	56.56%	56.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.790M	$2.546M	$2.550M
YoY Change	166.27%	22.23%	22.6%
Goodwill		$669.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$130.0K	$128.0K	$130.0K
YoY Change	0.0%	10.34%	-51.85%
Total Long-Term Assets	$7.250M	$3.343M	$3.350M
YoY Change	116.42%	10.77%	10.93%
TOTAL ASSETS
Total Short-Term Assets	$13.50M	$7.922M	$7.920M
Total Long-Term Assets	$7.250M	$3.343M	$3.350M
Total Assets	$20.75M	$11.27M	$11.27M
YoY Change	84.12%	39.45%	39.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.140M	$2.807M	$2.810M
YoY Change	11.74%	30.32%	30.7%
Accrued Expenses	$3.010M	$1.180M	$1.180M
YoY Change	155.08%	107.38%	107.02%
Deferred Revenue		$4.022M
YoY Change		-14.5%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$130.0K	$20.00K	$20.00K
YoY Change	550.0%	-33.33%	-33.33%
Total Short-Term Liabilities	$12.09M	$8.025M	$8.030M
YoY Change	50.56%	7.67%	7.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$3.350M	$151.0K	$1.000M
YoY Change	235.0%	0.0%	63.93%
Total Long-Term Liabilities	$3.350M	$151.0K	$1.000M
YoY Change	235.0%	0.0%	58.73%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.09M	$8.025M	$8.030M
Total Long-Term Liabilities	$3.350M	$151.0K	$1.000M
Total Liabilities	$15.43M	$9.027M	$9.030M
YoY Change	70.87%	11.79%	11.76%
SHAREHOLDERS EQUITY
Retained Earnings		-$70.70M
YoY Change		-0.18%
Common Stock		$72.94M
YoY Change		1.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00
YoY Change		-100.0%
Treasury Stock Shares		0.000 shares
Shareholders Equity	$5.320M	$2.137M	$2.240M
YoY Change
Total Liabilities & Shareholders Equity	$20.75M	$11.27M	$11.27M
YoY Change	84.12%	39.45%	39.48%

Cashflow Statement

Concept	2020	2019 Q2	2019
OPERATING ACTIVITIES
Net Income	-$2.093M	-$250.0K	$128.0K
YoY Change	-1735.16%	-60.32%	-108.67%
Depreciation, Depletion And Amortization	$825.0K	$180.0K	$606.0K
YoY Change	36.14%	63.64%	68.33%
Cash From Operating Activities	$2.905M	$250.0K	$1.862M
YoY Change	56.02%	2400.0%	-251.88%
INVESTING ACTIVITIES
Capital Expenditures	$2.220M	-$140.0K	$834.0K
YoY Change	166.19%	-33.33%	-32.14%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$2.220M	-$140.0K	-$834.0K
YoY Change	166.19%	-33.33%	-31.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$4.420M	-190.0K	$1.203M
YoY Change	267.41%	1800.0%	9153.85%
NET CHANGE
Cash From Operating Activities	$2.905M	250.0K	$1.862M
Cash From Investing Activities	-$2.220M	-140.0K	-$834.0K
Cash From Financing Activities	$4.420M	-190.0K	$1.203M
Net Change In Cash	$5.105M	-80.00K	$2.231M
YoY Change	128.82%	-61.9%	-191.47%
FREE CASH FLOW
Cash From Operating Activities	$2.905M	$250.0K	$1.862M
Capital Expenditures	$2.220M	-$140.0K	$834.0K
Free Cash Flow	$685.0K	$390.0K	$1.028M
YoY Change	-33.37%	77.27%	-141.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	16000	USD
CY2020Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	554000	USD
CY2019	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	14265000	USD
CY2020	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	16882000	USD
CY2019Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	99000	USD
CY2020Q2	csbr	Deferred Tax Liability Deferred Expense Depreciation And Amortization DeferredTaxLiabilityDeferredExpenseDepreciationAndAmortization	175000	USD
CY2019	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	77000	USD
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted	544000	USD
CY2019	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y3M19D
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y0M0D
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.70
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128000	USD
CY2019	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	49766	shares
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	11824	shares
CY2019	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P7Y10M25D
CY2020	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P8Y1M20D
CY2020Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	0	shares
CY2019	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	3.20
CY2020	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	7.96
CY2019	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised	905000	USD
CY2019	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0.000
CY2020	csbr	Effective Income Tax Rate Reconciliation Increase In Uncertain Tax Position EffectiveIncomeTaxRateReconciliationIncreaseInUncertainTaxPosition	0.015
CY2019	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.254
CY2020	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.150
CY2018Q3	csbr	Finance Lease Cost FinanceLeaseCost	266000	USD
CY2019Q4	csbr	Finance Lease Cost FinanceLeaseCost	231000	USD
	csbr	Finance Lease Cost FinanceLeaseCost	149000	USD
CY2019	csbr	Finance Lease Depreciationand Amortization Expenses FinanceLeaseDepreciationandAmortizationExpenses	490000	USD
CY2020	csbr	Finance Lease Depreciationand Amortization Expenses FinanceLeaseDepreciationandAmortizationExpenses	683000	USD
CY2018Q3	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	11000	USD
CY2019Q4	csbr	Finance Lease Monthly Payment FinanceLeaseMonthlyPayment	19000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due FutureMinimumLeasePaymentsDue	10139000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due In Five Years FutureMinimumLeasePaymentsDueInFiveYears	1002000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due In Four Years FutureMinimumLeasePaymentsDueInFourYears	1419000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due In Three Years FutureMinimumLeasePaymentsDueInThreeYears	1404000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due In Two Years FutureMinimumLeasePaymentsDueInTwoYears	1445000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due Next Twelve Months FutureMinimumLeasePaymentsDueNextTwelveMonths	1471000	USD
CY2019Q2	csbr	Future Minimum Lease Payments Due Thereafter FutureMinimumLeasePaymentsDueThereafter	3398000	USD
CY2019	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	0	USD
CY2020	csbr	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	235000	USD
CY2019	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	0	USD
CY2020	csbr	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	403000	USD
CY2020	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2013Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	12000000	USD
CY2020Q2	csbr	Operating Loss Carryforwards Limitations On Use Amount OperatingLossCarryforwardsLimitationsOnUseAmount	432000	USD
CY2019Q4	csbr	Present Value Minimum Future Obligations Interest Rate PresentValueMinimumFutureObligationsInterestRate	0.0475
CY2019	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	1465000	USD
CY2020	csbr	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	4455000	USD
CY2020	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised	10045000	USD
CY2019	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited	388000	USD
CY2020	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited	8587000	USD
CY2020	csbr	Stock Issued During Period Shares Stock Options And Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsAndWarrantsExercised	161000	shares
CY2013Q4	csbr	Stock Options Award Shares To Purchase Common Stock StockOptionsAwardSharesToPurchaseCommonStock	16667	shares
CY2019Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	1982000	USD
CY2020Q2	csbr	Trade Accounts Receivable TradeAccountsReceivable	2655000	USD
CY2020Q2	csbr	Working Capital WorkingCapital	1400000	USD
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-04-30
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12726728000000	shares
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q4	dei	Entity Public Float EntityPublicFloat	31000000	USD
CY2020	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2807000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3140000	USD
CY2019Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4399000	USD
CY2020Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	5059000	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4377000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4770000	USD
CY2019Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1180000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2502000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2074000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2772000	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	72924000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	77978000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	636000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	600000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	649000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	600000	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	22000	USD
CY2020Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	289000	USD
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4095066	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2271658	shares
CY2019Q2	us-gaap	Assets Assets	11265000	USD
CY2019Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4022000	USD
CY2020Q2	us-gaap	Assets Assets	20751000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	7922000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	13497000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	160000	USD
CY2019Q2	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	16000	USD
CY2019	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	235000	USD
CY2020	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	212000	USD
CY2020	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	300000	USD
CY2019Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1104000	USD
CY2020Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1551000	USD
CY2019Q2	us-gaap	Cash Cash	3200000	USD
CY2019Q2	us-gaap	Cash Cash	3237000	USD
CY2020Q2	us-gaap	Cash Cash	8300000	USD
CY2020Q2	us-gaap	Cash Cash	8342000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1006000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3237000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8342000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2231000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5105000	USD
CY2019Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2020Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11619538	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12726728	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11619538	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12726728	shares
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5815000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	101000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	127000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	103000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	130000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	USD
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	851000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	14953000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15411000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10460000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11174000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4207000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4109000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	385000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	303000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15000000	USD
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14953000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15411000	USD
CY2020Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15400000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	606000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	825000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	606000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	825000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.01
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.447
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.071
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.410
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.071
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.061
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.011
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0.038
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.002
CY2019	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2020Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	125000	USD
CY2019Q4	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	135000	USD
CY2020Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2000	USD
CY2019Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	366000	USD
CY2020Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	343000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88500	USD
CY2019	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	101000	USD
CY2020	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	127000	USD
CY2019Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	142000	USD
CY2020Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	181000	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	52000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4678000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6614000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	670000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	335000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	335000	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	231000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1845000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	103000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	130000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	653000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	333000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	531000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	670000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	611000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1322000	USD
CY2019	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-397000	USD
CY2020	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	0	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-682000	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1792000	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	27000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	77000	USD
CY2019	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2755933	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2019	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	6000	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	822000	USD
CY2019Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	0	USD
CY2020Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	4000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0725
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	16345000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	7268000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1697000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1867000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1844000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1818000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1851000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	9027000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	15433000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11265000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20751000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	8025000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12085000	USD
CY2020Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	178000	USD
CY2019Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	3358000	USD
CY2020Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	4475000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1203000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4420000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-834000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2220000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1862000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2905000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	128000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-2000000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-1975000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	128000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1975000	USD
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019	us-gaap	Operating Expenses OperatingExpenses	26797000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	33926000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	270000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-1803000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	955000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	503000	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	438000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3170000	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3709000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2798000	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3201000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0725
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y10M21D
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128000	USD
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	151000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	178000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	385000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-39000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-42000	USD
CY2016Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	742000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	834000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2220000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	308000	USD
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4300000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3900000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4620000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6765000	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2546000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3993000	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	71000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	277000	USD
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	262000	USD
CY2020	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	35000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4798000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5853000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70698000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72673000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72700000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	27067000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32123000	USD
CY2019	us-gaap	Revenues Revenues	2900000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3201000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	3056000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4242000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	636000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	600000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.85
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.65
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.030
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.018
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.026
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.013
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2133920	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1943618	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.83
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	66110	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	76669	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	9750	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	44813	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	206790	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	229833	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.03
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.33
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	5265000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	14557000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10663000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2705845	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2423626	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2271658	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.85
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.19
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.23
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	14557000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10663000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2423626	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2271658	shares
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.19
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.23
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	56529	USD
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.22
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.31
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	15.10
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.04
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.50
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.85
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.86
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.33
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13785000	USD
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	9898000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y11M0D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y6M0D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M25D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M19D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y3M19D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y0M0D
CY2019	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2000	USD
CY2020	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	3000	USD
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	363383	shares
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	248495	shares
CY2019	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6000	USD
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1465000	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4455000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	3000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	2238000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	5318000	USD
CY2019Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2417000	USD
CY2020Q2	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	2404000	USD
CY2018Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2019Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	151000	USD
CY2020Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	178000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	27000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	27000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14096117	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11843463	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11340184	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11843463	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11340184	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11843463	shares
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounts receivable realization, revenue recognition (replacement of licensed tumors), valuation allowance for deferred tax assets, valuation of goodwill, and stock-based compensation and warrant assumptions.  We base our estimates on historical experience, our observance of trends in particular areas and information or valuations and various other assumptions that we believe to be reasonable under the circumstances and which form the basis for making judgments about the carrying value of assets and liabilities that may not be readily apparent from other sources.  Actual amounts could differ significantly from amounts previously estimated.</font></div><div style="line-height:120%;text-align:justify;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

Files In Submission

Name	View Source	Status
0001628280-20-010734-index-headers.html	Edgar Link	pending
0001628280-20-010734-index.html	Edgar Link	pending
0001628280-20-010734.txt	Edgar Link	pending
0001628280-20-010734-xbrl.zip	Edgar Link	pending
csbr-20200430.xml	Edgar Link	completed
csbr-20200430.xsd	Edgar Link	pending
csbr-20200430_cal.xml	Edgar Link	unprocessable
csbr-20200430_def.xml	Edgar Link	unprocessable
csbr-20200430_lab.xml	Edgar Link	unprocessable
csbr-20200430_pre.xml	Edgar Link	unprocessable
csbr10-k4302020.htm	Edgar Link	pending
csbrex2314302020.htm	Edgar Link	pending
csbrex3114302020.htm	Edgar Link	pending
csbrex3124302020.htm	Edgar Link	pending
csbrex3214302020.htm	Edgar Link	pending
csbrex414302020.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2020 Form 10-K Financial Statement

#000162828020010734 Filed on July 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2020 Form 10-K Financial Statement

#000162828020010734 Filed on July 28, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr